VolitionRX Ltd’s filing revealed that its Director Innes Guy Archibald acquired Company’s shares for reported $10772.0 on Jun 03 ’25. In the deal valued at $0.54 per share,20,000 shares were bought. As a result of this transaction, Innes Guy Archibald now holds 888,689 shares worth roughly $0.5 million.
Then, Micallef Jacob Vincent bought 50,000 shares, generating $21,500 in total proceeds. Upon buying the shares at $0.43, the Chief Scientific Officer now owns 426,033 shares.
Before that, Reynolds Cameron John bought 20,000 shares. VolitionRX Ltd shares valued at $8,730 were divested by the President and CEO at a price of $0.44 per share. As a result of the transaction, Reynolds Cameron John now holds 2,319,222 shares, worth roughly $1.3 million.
H.C. Wainwright initiated its VolitionRX Ltd [VNRX] rating to a Buy in a research note published on April 08, 2025; the price target was $2.50. A number of analysts have revised their coverage, including The Benchmark Company’s analysts, who decreased its forecast for the stock in early February from “a Buy” to “a Hold”. Cantor Fitzgerald started covering the stock on March 10, 2021. It rated VNRX as “an Overweight”.
Price Performance Review of VNRX
On Tuesday, VolitionRX Ltd [AMEX:VNRX] saw its stock jump 0.74% to $0.56. Over the last five days, the stock has gained 4.06%. VolitionRX Ltd shares have fallen nearly -6.53% since the year began. Nevertheless, the stocks have fallen -18.72% over the past one year.
How much short interest is there in VolitionRX Ltd?
A steep rise in short interest was recorded in VolitionRX Ltd stocks on 2025-05-15, dropping by -0.15 million shares to a total of 0.35 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 0.5 million shares. There was a decline of -42.88%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 16, 2018 when Maxim Group began covering the stock and recommended ‘”a Buy”‘ rating along with a $6 price target.
